Synergy Capital Managers announce investment in Darl

11 Dec 2015

Synergy Capital Managers is  pleased to announce the completion of an investment in Darl Pharmaceuticals Limited by Synergy Private Equity Fund LP (SPEF). Darl is a fast growing pharmaceutical integrated value chain business with presence from production to last mile.

Since inception in 2010, Darl has consciously evolved into a strategic player in the supply chain for production and distribution of own-manufactured and contract manufactured pharmaceutical products across Ghana. Darl is focused on building a best-in-class integrated pharmaceutical operation establishing a dominant position in the market.

The investment in Darl is the first by SPEF in Ghana and the fourth overall since its first close in September 2014. This investment will enable the company undertake the expansion of its business including increasing manufacturing capacity and distribution footprint nationally.

Mr. David Ado, promoter and CEO of Darl Pharmaceuticals commenting on the investment said “ We are delighted about the investment of Synergy Private Equity Fund in Darl. With our current expansion, we expect to more than quadruple revenue within a year and further entrench our position in the market. Our goal is to be the number one brand in the pharmaceutical industry, offering unique selling experience using a rich talent of human resource. We know we can achieve our goal and attract more resources to enable us enter the sub-region.

In Darl, the Manager believes it has found value managers with a proven capacity to grow business as they have built the company from start-up to its present position achieving commendable year-on-year growth in the process. We are convinced that the company has great potential to establish a market leading position in the pharmaceutical industry in Ghana.

According to Akintoye Akindele, Partner, Synergy Capital Managers “Darl is a very interesting opportunity for us. We find the founders very impressive and they show the commitment that is required to build this franchise into a leading pharmaceutical business not just in Ghana, but also across the region in the future. We are very excited to partner with them to build a world-class business”.

Ghana represents an important market for us and we continue to see very attractive opportunities across numerous industry sectors. We are working to complete a couple more investments in Ghana in the coming months.

« Back to Member News

@deginvest_DE suscribes to bond issued by #HeliosTowers. Read more: https://t.co/57qJu6bhi8

Majority of recorded #VC deals (62%) between 2014-2019 had at least one VC fund manager involved, while 44% of reco… https://t.co/9NXleypzWr

@Proparco makes EUR30mn investment into @ActisLLP backed Douala Grand Mall. Read more: https://t.co/JfoGNzWgV8

@IFC_org provides Zenith Bank with US$100mn loan to support Nigerian SMEs. Read more: https://t.co/ON6U7P2kOb

Nearly one third (32%) of the total reported number of early stage investments in Africa between 2014-2019 were see… https://t.co/7JgWE9seBZ

;